Influence of Probiotics on Clinical Parameters, the Oral Microbiome and the Immune System During an Orthodontic Treatment in Adult Patients

Gingivitis Clinical Trial

Official title:

Influence of Probiotics on Clinical Parameters, the Oral Microbiome and the Immune System During an Orthodontic Treatment in Adult Patients: a Prospective, Double-blind, Randomized, Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04606186
• Other study ID #: ER-Ortho-Pro-RCT-Erw-2
• Status: Recruiting
• Phase: N/A
• Start date: October 19, 2020
• Est. completion date: November 1, 2023

Study information

• Verified date: May 2022
• Source: University of Erlangen-Nürnberg
• Contact: Corinna Lesley Seidel, Dr.
• Phone: ++49-09131-85-45667
• Email: corinna.boeck[@]uk-erlangen.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Orthodontic treatment with fixed appliances can be necessary to correct malocclusions in adolescence or adulthood. It its known that orthodontic treatment induces aseptic pseudo-inflammatory reactions. However, studies could show that an increase of certain inflammatory cytokines during orthodontic treatment correlated with a higher risk of root resorption. Moreover, it has been shown that orthodontic treatment leads to a dysbiosis of the oral microbiome especially during the first 3 months of the orthodontic treatment. This could be a potential risk factor as the inflammation of periodontitis during an orthodontic treatment could favor root resorption and progressive destruction of the periodontal apparatus.

Probiotics are already used successfully as an adjuvant therapy in the treatment of periodontitis to improve clinical parameters and to reduce local inflammation. However, there are only a few studies that investigated the influence of probiotics during an orthodontic treatment.

Therefore, the aim of our study is to investigate if the daily intake of lozenges containing probiotics versus placebo lozenges during the first 3 months of orthodontic treatment with fixed appliances can improve clinical parameters, reduce local inflammation, systemic inflammation and prevent a dysbiosis of the oral microbiome.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 34
• Est. completion date: November 1, 2023
• Est. primary completion date: November 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults (18 years and older) with fixed appliances undergoing orthodontic treatment.

• Signed declaration of consent by the patient

Exclusion Criteria:

• • Systemic or metabolic disease that are related to gingivitis or (e.g. diabetes) or could possibly influence the oral microbiome

• obesity:

• body mass index (BMI) > 30 kg/m² (weight and height will be measured)

• Eating disorder or underweight

• BMI < 18,5 kg/m² (weight and height will be measured)

• Above-average consumption of milk products: > 3 portions/day = >1,2 liters of milk or 1200g yoghurt/day (daily dose recommended by the german society for nutrition = 1-3 portions of milk products)

• allergy to ingredients of the lozenges

• intake of antibiotics or dietary supplementation (probiotics, vitamin C/D) in the last 6 months or during the study

• regular use of antibacterial mouth wash

• pregnancy

• smoking

• retraction of the declaration of consent by the patient

Related Conditions & MeSH terms

• Gingivitis
• Inflammation
• Orthodontic Appliance Complication
• Periodontal Inflammation

Intervention

Dietary Supplement:
• Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)
Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
• Placebo-lozenges (BioGaia)
Placebo-lozenges (BioGaia)

Locations

Country	Name	City	State
Germany	Department of Orthodontics and Orofacial Orthopedics	Erlangen

Sponsors (2)

Lead Sponsor	Collaborator
University of Erlangen-Nürnberg	BioGaia AB

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adverse events	Collection of adverse events	Baseline till 12 months after insertion of appliance
Primary	Gingival Index (GI)	Primary endpoint is the change of the Gingival Index (GI) from baseline to week 4. The measurement of GI is described by Löe et al, which scores the gingival condition according to the defined criteria. The scores will be measured at four sites per tooth, added and divided by four to obtain the "GI for the tooth"-Index. We will use the 'GI for the tooth' described there, but only for those teeth with fixed ortodontic brackets. The 'GI for the patient' is then the mean of the GIs for the teeth.; CRITERIA FOR THE GINGIVAL INDEX SYSTEM; 0 = Absence of inflammation.; = Mild inflammation - slight cliange in color and little change in texture.; = Moderate inflammation - modcrate glazing, redness,oedema, hypertrophy, bleeding on pressure.; = Severe inflammation - marked redness and hypertrophy, tendency to spontaneous bleeding, ulceration.	Baseline to week 4 of intake
Secondary	Probing pocket depth (PPD) (4-point-measurement)	The measurement of the probing of periodontal pockets (periodontal probing depth, PPD) is performed according to standardized protocols: insertion of a perdiotonal probe into the gingival sulcus with a force of 0.2-0.3 N; probing depth is read out at landmarks on the periodontal prove. The scores will be measured at four sites per tooth, added and divided by four to obtain the "PPDI for the tooth"-Index. We will use the 'PPD for the tooth', but only for those teeth with fixed ortodontic brackets. The 'PPD for the patient' is then the mean of the PPDs for the teeth.	Baseline till 12 months after insertion of appliance
Secondary	Modified Plaque Index (MPI)	The measurement of Modified plaque index (MPI) is described by Attin et al, which scores the amount of plaque according to the defined criteria. The score will be measured at each tooth, but only for those teeth with fixed ortodontic brackets. The 'Modified plaque index for the patient' is then the mean of the MPIs per teeth: Index = (Sum of MPI per tooth×100)/ (3×number of measured teeth).; CRITERIA FOR THE MODIFIED PLAQUE INDEX; 0 = no plaque; = small plaque areas approximal; = small plaque areas approximal + cervical; = plaque covers 1/3 of the cervical area of the bracket.	Baseline till 12 months after insertion of appliance
Secondary	Local cytokine expression	Samples from different oral niches (saliva, soft and hard tissue samples, gingival crevicular fluid) will be collected to analyse local inflammation: Unstimulated saliva will be gained by the spitting method, soft tissue samples will be collected in using sterile swabs, hard tissue samples of supragingival plaque will taken by sterile curettes and samples of gingival sulcus fluid will be collected from 6 periodontal pockets of the mesio-buccal side of defined teeth (Ramfjord teeth: 16,21,24,36,41,44) using sterile paper strips. Sulcus fluid flow rate will be performed using Periotron 8000. The cytokine concentration (in pg/mL) of granulocyte-macrophage colony-stimulating-factor (GM-CSF), interferon (IFN)- gamma, interleukin (IL)-2, IL-4, IL-6, IL-8 and IL-10 as well as tumor necrosis factor (TNF) in defined oral niches will be measured using multiplex immunoassay.	Baseline till 12 months after insertion of appliance
Secondary	Oral microbiome	Samples from different oral niches (saliva, soft and hard tissue samples, gingival crevicular fluid) will be collected to analyse the oral microbiome: Unstimulated saliva will be gained by the spitting method, soft tissue samples will be collected in using sterile swabs, hard tissue samples of supragingival plaque will taken by sterile curettes and samples of gingival sulcus fluid will be collected from 6 periodontal pockets of the mesio-buccal side of defined teeth (Ramfjord teeth: 16,21,24,36,41,44) using sterile paper strips. Composition of the oral microbiome will be analysed using 16 S rRNA sequencing and operational taxonomic units (OTUs) will be classified according to SILVA database.	Baseline till 12 months after insertion of appliance
Secondary	Systemic cytokine expression	Samples of peripheral whole blood will be taken. Measurement of systemic cytokine concentration in serum (in pg/mL) will be performed using Enzyme-linked immunosorbent assay (ELISA). To analyse systemic inflammation and a possible Th1-/Th2- or Th-17 shift, cytokines representing the Th1-/Th-2/Th-17 cytokine profile (e.g. TNF, Interferon-Gamma,Interleukin 10) will be measured.	Baseline till 12 months after insertion of appliance
Secondary	Cellular immunity	Samples of peripheral whole blood will be taken.Composition of immunoregulatory cells in the mononuclear cell fraction (MNC) will be analysed using samples of peripheral blood and MNC isolation. The cellular immune status will be analysed quantitatively (in %: relative percentual distribution in the MNC fraction) using fluor-activated cell scanning (FACS). Lymphocyte typing will be performed using an inflammatory Panel: e.g. CD4+ T cells, CD8+ T cells, CD19+ B cells, CD16+/CD56+ NK cells, CD4+/CD25+/CD127low regulatory T cells, CD45RA/CD45RO naive/memory T cells and activated immune cells.	Baseline till 12 months after insertion of appliance